Compositions and Methods for Eliciting an Immune Response to Escape Mutants of Targeted Therapies
AssigneeGlobelmmune, Inc.
InventorsDavid Apelian, Alex Franzusoff, Timothy C. Rodell
Life of this patent
Estimating the term…
Abstract
Provided herein are cells, vectors and viruses in association with a mutant polypeptide that has emerged in response to a therapeutic or prophylactic agent; compositions comprising such cells, vectors and viruses and methods for their use in eliciting an immune response to the mutant polypeptide. In some examples, the immune response is a cellular immune response.
Claims22
A composition comprising one or more of the following:
- i) a yeast vehicle comprising nucleic acid which encodes at least one mutant polypeptide, a fragment thereof that comprises a mutation, or a mimetope;
- ii) a yeast vehicle comprising at least one mutant polypeptide, a fragment thereof that comprises a mutation, or a mimetope;
- iii) a yeast vehicle in association with at least one mutant polypeptide, a fragment thereof that comprises a mutation, or a mimetope;
- iv) a yeast vehicle comprising nucleic acid which encodes at least one mutant polypeptide, a fragment thereof that comprises a mutation, or a mimetope loaded intracellularly into a dendritic cell;
- or
- v) a yeast vehicle and at least one mutant polypeptide, a fragment thereof that comprises a mutation, or a mimetope loaded intracellularly into a dendritic cell,
- wherein the mutant polypeptide is known to emerge or has emerged with at least one specific mutation in response to administration of a targeted therapeutic and/or prophylactic agent.
(canceled)
5-7. (canceled)
9-16. (canceled)
(canceled)
20-46. (canceled)
49-66. (canceled)
A method for ameliorating a symptom of cancer in a mammal, wherein the cancer is a recurring cancer resulting from an escape mutation that emerges in response to administration of imatinib comprising administration to the mammal of an effective amount of a composition comprising one or more of the following:
- a) a yeast vehicle transformed with and expressing a nucleic acid molecule which encodes a Bcr-Abl or an immunogenic domain thereof, wherein the Bcr-Abl or immunogenic domain thereof comprises the escape mutation that emerges in response to administration of imatinib;
- b) a yeast vehicle comprising Bcr-Abl or an immunogenic domain thereof, wherein the Bcr-Abl or immunogenic domain thereof comprises the escape mutation that emerges in response to administration of imatinib;
- c) a yeast vehicle in association with Bcr-Abl or an immunogenic domain thereof, wherein the Bcr-Abl or an immunogenic domain thereof comprises the escape mutation that emerges in response to administration of imatinib;
- d) a yeast vehicle transformed with and expressing a nucleic acid molecule which encodes Bcr-Abl or an immunogenic domain thereof, wherein the Bcr-Abl or an immunogenic domain thereof comprises the escape mutation that emerges in response to administration of imatinib, the yeast vehicle loaded intracellularly into a dendritic cell;
- or
- e) a yeast vehicle comprising Bcr-Abl or an immunogenic domain thereof, wherein the Bcr-Abl or an immunogenic domain thereof comprises the escape mutation that emerges in response to administration of imatinib, the yeast vehicle loaded intracellularly into a dendritic cell;
- f) wherein administration of the composition ameliorates a symptom of cancer in the mammal.
Dependencies are inferred from the claim text.